Skip to main content
. Author manuscript; available in PMC: 2023 Mar 25.
Published in final edited form as: Gynecol Oncol. 2020 Dec 13;160(2):568–578. doi: 10.1016/j.ygyno.2020.12.004

Table 1.

Summary of immunohistochemistry results in COV434 and TOV-112D original tumours.

COV434 TOV-112D
Antibody Staining Slide Well differentiated Undifferentiated Slide
SMARCA4 Negative Whole Positive Negative Whole
SMARCA2 Negative Whole Positive Negative Whole
SMARCB1 Positive Whole Positive Positive Whole
WT1 Positive Whole Negative Negative Whole
p53 Wild type Whole# Missense mutant Missense mutant Whole
FOXL2 Negative Whole Negative Negative TMA
Inhibin A Negative Whole Negative Negative TMA
Calretinin ND Negative Negative TMA
MMR proteins## Intact Whole Intact Intact TMA
AE1/AE3 ND Positive Negative Whole
MOC31 ND Positive Negative TMA
Claudin-4 ND Positive Negative TMA
EMA ND Positive, patchy Negative TMA
PAX8 ND Negative Negative TMA
p16 ND Negative Diffuse strong Whole
ER ND Positive Negative Whole
PR ND Positive Negative Whole
Napsin A ND Negative Negative Whole
HNF1 beta ND Negative Negative Whole
ARID1A ND Positive Positive Whole
PTEN ND Positive Positive Whole
CD10 Negative Whole ND ND
synaptophysin Negative Whole ND ND
chromogranin Negative Whole ND ND
CD56 Negative Whole ND ND

Notes:

#

, staining was done on whole slides of cell line xenografted tumour;

##

, mismatch repair (MMR) proteins include MLH1, MSH2, MSH6 and PMS2; ND, not determined.